AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
_10_18_2024_02_37_38_683583.jpg)
Highlights
- Chimeric Therapeutics has initiated the first-in-human Phase 1/2 trial for CHM CDH17.
- Following the milestone announcement, there was a significant 15.79% surge in CHM’s shares on the ASX.
- Preclinical studies demonstrated that CDH17 CAR T effectively eradicated tumours in seven different cancer models without inducing toxicity in normal tissues.
Chimeric Therapeutics (ASX: CHM) has reached a noteworthy milestone in its endeavour to address critical medical challenges.
The Australian company has commenced the first-in-human study for its Phase 1/2 multi-centre clinical trial of CHM CDH17 cell therapy with the enrolment of the first participant.
Following the announcement, Chimeric's shares surged by 15.79% on the ASX during Monday afternoon trading.
First-in-human study
The Phase 1/2 trial (NCT06055439) is a two-stage study for bowel cancer patients with significant unmet needs.
Data source: Company update
According to the company, this trial marks a significant advancement in the application of cell therapies for solid tumours. Additional clinical trial sites are anticipated to commence operations in the second half of 2024.
CHM CDH17 - A 3rd generation, novel CAR T cell therapy
Data source: Company update
These experiments demonstrated that CDH17 CAR T was able to eradicate established tumours in seven cancer models with no toxicity to normal tissues.
Reflecting on the clinical trial, Xianxin Hua added “It is exciting to see the advancement from the development of the CDH17 CAR T technology in our laboratory to the enrollment of the first patient in this Phase 1/2 study”.
Chimeric has a varied portfolio encompassing first-in-class autologous CAR T cell therapies and best-in-class allogeneic NK cell therapies. These assets are under development across various oncological disease areas, with three ongoing clinical programs and intentions to launch further clinical initiatives in 2024.
CHM shares were trading at AU$0.022 at the time of writing on 22 July 2024.
